Longevity Vision Fund
Longevity Vision Fund is a venture capital firm established in 2019 and based in New York. With a focus on making longevity affordable and accessible, the firm manages a $100 million investment fund dedicated to accelerating breakthroughs in extending healthy human lifespans. It invests in companies engaged in preventive medicine, early detection, medical technologies, artificial intelligence in healthcare, longevity therapies, regenerative medicine, and healthcare infrastructure. The fund provides financing from Seed to Series C stages for biotech and life extension-focused companies that exhibit the potential for affordable longevity solutions and a clear vision for achieving significant milestones and market validation. As a Registered Investment Adviser, Longevity Vision Fund aims to drive innovation in the longevity sector.
Juvenescence Limited is a British Virgin Islands-based holding company focused on investing in human aging and longevity. The company has raised substantial capital to establish a comprehensive ecosystem aimed at addressing aging, age-related diseases, and regeneration. Juvenescence aims to leverage recent scientific advancements to develop therapeutics that can significantly extend human healthspan and lifespan. The company's approach involves creating and partnering with new ventures that specialize in longevity-related therapies, in-licensing promising compounds from academic and industry sources, and collaborating with leading scientists and research institutions. Their work is grounded in a modern understanding of the biological mechanisms of aging, allowing them to create evidence-based treatments for age-associated diseases. Ultimately, Juvenescence seeks to enhance both lifespan and healthspan by developing therapies that slow the aging process and promote rejuvenation.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.